NCT04336826Phase 2Completed

A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Study sponsor: PTC Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-08-07Actual
Enrollment · participants6Actual
Source updated2024-04-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview